Zelira Therapeutics Limited (ZLDAF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Zelira Therapeutics Limited (ZLDAF) Healthcare & Pipeline Overview

Zelira Therapeutics Limited (ZLDAF) specializes in the research and development of cannabinoid-based therapeutics, aiming to address unmet medical needs through clinically validated formulations and strategic partnerships.

What Is the Investment Thesis for ZLDAF?

Zelira Therapeutics Limited presents a unique investment thesis centered around its innovative approach to cannabinoid-based therapeutics. The company's focus on clinically validated medicines, such as Zenivol for chronic insomnia, positions it well in a growing market. The global cannabinoid market is projected to reach $55.8 billion by 2028, driven by increasing acceptance of cannabis-derived products for medical use. Zelira's strategic partnerships with leading research institutions enhance its credibility and potential for successful product development. However, the company faces risks associated with its small market capitalization of $3.42M and the inherent challenges of OTC trading, including liquidity concerns. Investors should closely monitor the progress of clinical trials and regulatory approvals, as these will be critical in determining the company's future growth trajectory.

Based on FMP financials and quantitative analysis

ZLDAF Key Highlights

Market capitalization of $3.42M indicates a small but focused company in the biopharmaceutical sector.

• Profit margin of -553873.6% reflects the early-stage nature of the company's development and commercialization efforts.
• Gross margin of -122587.0% highlights the challenges in achieving profitability as the company invests in research and development.
• Beta of 0.59 suggests lower volatility compared to the broader market, indicating a potentially stable investment environment.
• No dividend yield as the company is reinvesting earnings into product development and clinical trials.

Who Are ZLDAF's Competitors?

ZLDAF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ZLDAF's Key Strengths?

Innovative focus on cannabinoid-derived therapeutics.

• Strong partnerships with leading research institutions.
• Niche market positioning in the biopharmaceutical sector.
• Potential for significant growth in the expanding cannabinoid market.

What Are ZLDAF's Weaknesses?

Small market capitalization limits financial flexibility.

• Negative profit margins indicate early-stage development challenges.
• Limited product portfolio compared to larger competitors.
• Dependence on successful clinical trials for future growth.

What Could Drive ZLDAF Stock Higher?

Clinical trial results for Zenivol expected in Q4 2026.

• Expansion of HOPE brand formulations into additional U.S. states.
• Potential partnerships with new research institutions for product development.
• Development of ITURA and other OTC products to meet market demand.
• Regulatory approvals for new cannabinoid-based therapies in various markets.

What Are the Key Risks for ZLDAF?

Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.

• Regulatory changes impacting the cannabis industry.
• Competition from larger pharmaceutical companies with established products.
• Market volatility associated with trading on the OTC market.
• Financial challenges due to negative profit margins and limited resources.

What Are the Growth Opportunities for ZLDAF?

• Expansion of HOPE Brand Formulations: Zelira's HOPE brand formulations are currently available in Pennsylvania and Louisiana. As the acceptance of cannabinoid-based products grows, there is potential for expansion into additional states and markets. This could significantly increase revenue streams, especially as more states legalize medical cannabis, potentially increasing the market size to over $20 billion in the U.S. alone by 2025.
• Development of Zenivol: The ongoing development of Zenivol, a cannabinoid-based medicine for chronic insomnia, represents a significant growth opportunity. With insomnia affecting approximately 30% of adults, the potential market for Zenivol is substantial. If successful in clinical trials, Zelira could capture a significant share of the insomnia treatment market, projected to reach $4.5 billion by 2028.
• Introduction of ITURA: Zelira's ITURA topical cream addresses symptoms related to Peripheral Artery Disease and diabetes, targeting a market that is growing due to rising diabetes prevalence. The global diabetes care market is expected to reach $100 billion by 2026, providing a lucrative opportunity for Zelira to expand its product offerings.
• Strategic Partnerships: Zelira's collaborations with institutions like Curtin University and the Telethon Kids Institute enhance its research capabilities and credibility. These partnerships could lead to accelerated product development and clinical validation, positioning the company favorably in the competitive landscape of cannabinoid therapeutics.
• Over-the-Counter Product Expansion: The company’s OTC offerings, such as SprinJene and RAF FIVE, provide additional revenue streams. As consumer interest in natural and alternative therapies increases, Zelira can leverage its existing products and expand its OTC portfolio to capture a larger share of the market, which is expected to grow significantly in the coming years.

What Are ZLDAF's Competitive Advantages?

• Focus on clinically validated cannabinoid medicines differentiates Zelira from competitors.
• Strategic partnerships with reputable research institutions enhance credibility.
• Niche market focus on cannabinoid therapies provides a unique positioning.
• Innovative product offerings targeting unmet medical needs create a competitive edge.
• Strong emphasis on research and development fosters continuous innovation.

What Does ZLDAF Do?

Zelira Therapeutics Limited, established in 2003 and headquartered in Perth, Australia, is a biopharmaceutical company that focuses on the research, development, and commercialization of cannabinoid-derived therapeutic agents. Originally named Zelda Therapeutics Limited, the company rebranded in December 2019 to reflect its commitment to advancing cannabinoid medicine. Zelira's product offerings include the HOPE brand formulations available in Pennsylvania and Louisiana, alongside its flagship product, Zenivol, designed specifically for chronic insomnia. The company also markets several over-the-counter (OTC) products, such as SprinJene for oral care and RAF FIVE for dermatological applications. A notable OTC product is ITURA, a topical cream aimed at alleviating symptoms associated with Peripheral Artery Disease and diabetes, including numbness and muscle cramps. Zelira Therapeutics has established strategic partnerships with reputable institutions such as Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia to enhance its research capabilities and clinical validation processes. With a small team of eight employees, the company is positioned to leverage its niche focus on cannabinoid therapeutics, which differentiates it from traditional pharmaceutical firms.

What Products and Services Does ZLDAF Offer?

• Research and develop cannabinoid-derived therapeutic agents.
• Commercialize cannabinoid-based medicines for various medical conditions.
• Market the HOPE brand formulations in select U.S. states.
• Develop Zenivol, a medicine targeting chronic insomnia.
• Offer OTC products like SprinJene for oral care and ITURA for dermatological applications.
• Cultivate partnerships with leading research institutions for enhanced clinical validation.

How Does ZLDAF Make Money?

• Generate revenue through the sale of prescription cannabinoid-based medicines.
• Market OTC products to consumers, diversifying revenue streams.
• Leverage partnerships for research funding and product development.
• Focus on clinical trials to validate product efficacy and safety.
• Aim for regulatory approvals to enhance market access and credibility.

What Industry Does ZLDAF Operate In?

The biotechnology industry is experiencing significant growth, driven by advancements in medical research and increasing demand for innovative therapies. The global cannabinoid market, in particular, is expected to grow at a CAGR of 22.2% from 2021 to 2028, reaching an estimated $55.8 billion. Zelira Therapeutics Limited operates within this expanding market, focusing on cannabinoid-derived therapeutics, which are gaining traction due to their potential benefits in treating various medical conditions. The competitive landscape includes established pharmaceutical companies and emerging biotech firms, making clinical validation and strategic partnerships crucial for market positioning.

Who Are ZLDAF's Key Customers?

• Patients seeking cannabinoid-based treatments for medical conditions.
• Healthcare providers prescribing cannabinoid therapies.
• Consumers purchasing OTC products for personal care.
• Research institutions collaborating on product development.
• Pharmacies and distributors selling Zelira's products.

Zelira Therapeutics Limited Financial Trajectory

Zelira Therapeutics Limited (ZLDAF) reported $0.658 in revenue for Q2 2025, a decline of 99.9% compared to the prior quarter. The company recorded a net loss of $1.2M, with diluted EPS of $-0.10. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely.

Company Profile

Zelira Therapeutics Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Perth, AU. The company is led by CEO Oludare Odumosu. ZLDAF has traded publicly since 2017.

How Zelira Therapeutics Limited Is Valued

Zelira Therapeutics Limited carries a market capitalization of $3.42M, placing it in the micro-cap category. Relative to its peer group, ZLDAF's quantitative score of 47/100 is roughly in line with the peer average of 57/100.

Return on equity for Zelira Therapeutics Limited stands at 80.8%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -74.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.11 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -63.2%, the inverse of the P/E and a quick read on earnings relative to price.

Zelira Therapeutics Limited's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

ZLDAF Financials

ZLDAF Latest News

No recent news available for ZLDAF.

ZLDAF Analyst Consensus

ZLDAF MoonshotScore

Zelira Therapeutics Limited Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources